Cover Image

Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

Objective: The ORIENT-32 clinical trial revealed that sintilimab plus bevacizumab biosimilar significantly improved the median progression-free survival and median overall survival (OS) compared with sorafenib. This analysis evaluated the cost-effectiveness of sintilimab plus bevacizumab biosimilar...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ye Peng (Author), Xiaohui Zeng (Author), Liubao Peng (Author), Qiao Liu (Author), Lidan Yi (Author), Xia Luo (Author), Sini Li (Author), Liting Wang (Author), Shuxia Qin (Author), Xiaomin Wan (Author), Chongqing Tan (Author)
Format:	Book
Published:	Frontiers Media S.A., 2022-02-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
by: Ting Zhou, et al.
Published: (2022)

Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer
by: Xia Luo, et al.
Published: (2022)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer
by: Meiyu Wu, et al.
Published: (2022)

Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer
by: Tan Chongqing, et al.
Published: (2021)

Cost-Effectiveness Analysis of Hepatic Arterial Infusion Chemotherapy of Infusional Fluorouracil, Leucovorin, and Oxaliplatin Versus Transarterial Chemoembolization in Patients With Large Unresectable Hepatocellular Carcinoma
by: Haixia Zhang, et al.
Published: (2022)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
by: Qiao Liu, et al.
Published: (2022)

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer
by: Xiaomin Wan, et al.
Published: (2021)

The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China
by: Rui Meng, et al.
Published: (2022)

Cost-effectiveness analysis of first-line sintilimab plus chemotherapy vs. chemotherapy alone for unresectable advanced or metastatic gastric or gastroesophageal junction cancer in China
by: Zuojuan Xiang, et al.
Published: (2024)

TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma
by: Ying Wu, et al.
Published: (2020)

First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis
by: Qiao Liu, et al.
Published: (2021)

Sorafenib and Everolimus for paediatric patients with unresectable osteosarcoma
by: Shilpa Vijayasrinivasan, et al.
Published: (2017)

Cure can be achieved by conversion to microwave ablation following atezolizumab-bevacizumab therapy in unresectable hepatocellular carcinoma
by: Rene John D. Febro, et al.
Published: (2024)

Economic Evaluation of Dapagliflozin in the Treatment of Patients With Heart Failure: A Systematic Review
by: Meiyu Wu, et al.
Published: (2022)

A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
by: Yukinobu Watanabe MD, PhD, et al.
Published: (2021)

Benefit-to-harm ratio and cost-effectiveness of government-recommended gastric cancer screening in China: A modeling study
by: Shuxia Qin, et al.
Published: (2022)

A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Napabucasin Combined with Sorafenib in Japanese Patients with Unresectable Hepatocellular Carcinoma
by: Takuji Okusaka, et al.
Published: (2023)

Early Clinical Outcomes of Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma: A Real-World Comparison with First-Line or Later-Line Treatment
by: Yudai Fujiwara, et al.
Published: (2024)

Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis
by: Jeayeon Park, et al.
Published: (2024)

Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab
by: Tae Hyun Kim, et al.
Published: (2023)

Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
by: Pingyu Chen, et al.
Published: (2022)

Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States
by: SiNi Li, et al.
Published: (2021)

Radiotherapy plus lenvatinib versus radiotherapy plus sorafenib for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study
by: Min Zhang, et al.
Published: (2024)

Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab
by: Di Cao, et al.
Published: (2023)

Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis
by: Cheng Huang, et al.
Published: (2021)

Exposure-response analysis using time-to-event data for bevacizumab biosimilar SB8 and the reference bevacizumab
by: Suemin Park, et al.
Published: (2024)

Letter regarding "Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab"
by: Sun Hyun Bae, et al.
Published: (2023)

Outcome of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma
by: Hadeel A Helmi, et al.
Published: (2020)

Efficacy and safety of sintilimab plus doxorubicin in advanced soft tissue sarcoma: A single-arm, phase II trial
by: Zhichao Tian, et al.
Published: (2022)

Immune Checkpoint Inhibitors Plus an Anti-VEGF Antibody as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis
by: Lu Li, et al.
Published: (2022)

Favorable response of hepatocellular carcinoma with portal vein tumor thrombosis after radiotherapy combined with atezolizumab plus bevacizumab
by: Yong Tae Kim, et al.
Published: (2023)

Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis
by: Hongfu Cai, et al.
Published: (2024)

Anti-PD-1/L1 antibody plus anti-VEGF antibody vs. plus VEGFR-targeted TKI as first-line therapy for unresectable hepatocellular carcinoma: a network meta-analysis
by: Yiwen Zhou, et al.
Published: (2024)

Successful neoadjuvant chemotherapy plus sintilimab for locally advanced cervical cancer: case series and review of the literature
by: Linlin Liu, et al.
Published: (2023)

A case of successful surgical treatment for peritoneal seeding of hepatocellular carcinoma after radiotherapy and atezolizumab plus bevacizumab combination treatment
by: Yuri Cho, et al.
Published: (2023)

Potential tactics with certain gut microbiota for the treatment of unresectable hepatocellular carcinoma
by: Sayuri Yoshikawa, et al.
Published: (2023)

First-line sintilimab plus chemotherapy in locally advanced or metastatic esophageal squamous cell carcinoma: A cost-effectiveness analysis from China
by: Jian Shen, et al.
Published: (2022)

Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study
by: Xu Y, et al.
Published: (2023)

Cost-effectiveness analysis of camrelizumab plus paclitaxel and carboplatin versus sintilimab plus gemcitabine and cisplatin or carboplatin for the first-line treatment of local advanced or metastatic squamous NSCLC in Chinese mainland
by: Xiaoting Liu, et al.
Published: (2024)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
by: Qingli Cui, et al.
Published: (2022)